Systematic review of incretin therapy during peri-operative and intensive care

Abraham H Hulst1, Mark P Plummer2, Markus W Hollmann1, J Hans DeVries3, Benedikt Preckel1*, Adam M Deane2 and Jeroen Hermanides1

Abstract

**Background:** Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones. By lowering blood glucose in a glucose-dependent manner, incretin-based therapies represent a novel and promising intervention to treat hyperglycaemia in hospital settings. We performed a systematic review of the literature for all current applications of incretin-based therapies in the peri-operative and critical care settings.

**Methods:** We searched MEDLINE, the Cochrane Library, and Embase databases for all randomised controlled trials using exogenous GLP-1, GLP-1 receptor agonists, exogenous GIP and dipeptidyl peptidase IV inhibitors in the setting of adult peri-operative care or intensive care. We defined no comparator treatment. Outcomes of interest included blood glucose, frequency of hypoglycaemia and insulin administration.

**Results:** Of the 1190 articles identified during the initial literature search, 38 fulfilled criteria for full-text review, and 19 single-centre studies were subsequently included in the qualitative review. Of the 18 studies reporting glycaemic control, improvement was reported in 15, defined as lower glucose concentrations in 12 and as reduced insulin administration (with similar glucose concentrations) in 3. Owing to heterogeneity, meta-analysis was possible only for the outcome of hypoglycaemia. This revealed an incidence of 7.4% in those receiving incretin-based therapies and 6.8% in comparator groups ($P = 0.94$).

**Conclusions:** In small, single-centre studies, incretin-based therapies lowered blood glucose and reduced insulin administration without increasing the incidence of hypoglycaemia.

**Trial registration:** PROSPERO, CRD42017071926.

**Keywords:** DPP-IV inhibitors, GIP, GLP-1, Glucose control, Hyperglycaemia, Hypoglycaemia, Intensive care, Peri-operative care

Background

Hyperglycaemia occurs frequently in the peri-operative period and during critical illness, even in patients without a history of diabetes mellitus [1–3]. Usual management of hyperglycaemia in these settings primarily involves intravenous infusions of insulin, with the dose titrated according to intermittent measurement of blood glucose [4]. This strategy is somewhat complicated and labour-intensive, and it increases the risk of hypoglycaemia and glycaemic variability, which are both associated with adverse outcome [3, 5–10].

The incretin effect is the physiological phenomenon observed following the ingestion of glucose, which results in endogenous insulin secretion almost two-fold greater than after a comparable intravenous glucose load [11]. This process is attributed to the enterohormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) that have insulinotropic and glucagonostatic properties [12]. The insulinotropic response is glucose-dependent, meaning that even when GLP-1 and GIP are administered in pharmacological doses, there is negligible risk of hypoglycaemia [12].

GLP-1 and GIP are rapidly metabolised by the enzyme dipeptidyl peptidase IV (DPP-IV) [12]. Accordingly, incretin-based therapies necessitate a continuous infusion of either exogenous GLP-1 or GIP, administration
of a DPP-IV-resistant receptor agonist (GLP-1 receptor agonists, first-in-class drug exenatide), or a DPP-IV antagonist that increases endogenous GLP-1 and GIP concentrations (first-in-class drug sitagliptin) [12]. All currently available and applicable drugs are named in Additional file 1.

GLP-1 receptor agonists and DPP-IV inhibitors are now established therapies for the management of patients with type 2 diabetes mellitus (T2DM) [13]. The efficacy and safety profiles of incretin-based therapies have fostered enthusiasm for use of these agents as adjuncts or alternatives to insulin for glycaemic control in the operating room and intensive care unit (ICU). The purpose of this systematic review was to evaluate the safety and efficacy of incretin therapies for glucose control in the operating room and ICU.

Methods
This systematic review was prospectively registered in the PROSPERO database (PROSPERO identifier CRD 42017071926) and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [14].

Eligibility criteria
Studies eligible for inclusion were prospective randomised controlled trials using an incretin-based therapy in the operating room and/or the ICU. Studies published in any language and without publication date restriction were considered. Paediatric, animal and observational studies were excluded.

Search strategy
We performed an unrestricted electronic database search of the MEDLINE, Cochrane Library and Embase databases from their inception to 13 February 2018. Our search included terms to specify the intervention (incretin therapy), setting (peri-operative and ICU care) and study type (prospective randomised controlled trials). Searches included synonyms and combinations of the following terms: ‘operating room’, ‘OR’, ‘peri-operative period’, ‘ICU’, ‘critical care’, ‘incretin therapy’, ‘GLP-1’, ‘GIP’ and ‘DPP-IV inhibitor’, as well as generic names of the currently marketed forms of these medications. Our complete search terms and methodology are available as additional material (see Additional file 1) and accessible via PROSPERO. Reference lists of retrieved papers were also reviewed for potentially eligible studies not captured in the primary search. We defined no specific comparator for any intervention.

Study selection
After deletion of duplicate studies, two investigators (AHH, MPP) screened all titles and abstracts using Rayyan [15]. Relevant studies were then evaluated in full text for eligibility, with any conflicts resolved by a third investigator (JH). The authors of conference abstracts and published protocols without subsequent full texts were contacted to request the data and/or manuscript.

Risk-of-bias assessment
Two authors independently assessed the quality of the research methodology of all randomised controlled trials using the Cochrane Collaboration’s Risk of Bias Tool [16].

Data extraction
We extracted data including study characteristics (author, publication year, country, design, funding source and sample size), setting (operating room, ICU, post-cardiac surgery), patient characteristics (demographics) and intervention and comparator parameters (incretin therapy, route, dose and duration, as well as additional treatments). We did not predefine primary outcomes in this scoping exploratory systematic review; all reported outcomes were recorded and summarised if reported across multiple studies. Owing to the expected heterogeneity of interventions, comparators, settings and outcomes, we did not plan a meta-analysis of outcomes. Owing to the frequency with which hypoglycaemia was reported across studies, we decided to retrospectively perform a meta-analysis of this outcome. This was not feasible for all other outcomes.

Statistical analysis
For data extraction and meta-analysis, we used Review Manager version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). We used a random effects model because of expected clinical heterogeneity between trials. Results of the meta-analysis were expressed as Mantel-Haenszel odds ratios with 95% CIs because of the dichotomous outcome. As markers for inter-trial heterogeneity, we used $I^2$, $\chi^2$ and $P$ statistics.

Results
Our search yielded 1126 citations, and after elimination of duplicates, abstracts and full texts, 19 studies were included in this systematic review (Fig. 1).

Study characteristics
Characteristics of the included studies are summarised in Table 1, including setting of care, duration, type and dose of intervention, and reported outcomes [17–34]. In total, 1410 patients participated in these studies, of whom 988 were known to have T2DM. All studies recruited patients in a single centre. Comparator groups included placebo or combinations of intravenous or subcutaneous insulin.
Risk of bias
A summary of the risk of bias in the included studies is presented in Figs. 2 and 3. Randomisation sequence generation was often briefly described and therefore assessed as unclear. Allocation concealment carried a low risk of bias in most studies and was scored as unclear only if it remained unmentioned in the manuscript. Most trials were blinded and adequately described as such. In some trials the intervention was not blinded; however, if the primary outcome was a measurable physiological variable (e.g., glucose), a low risk of bias was ascribed. Only one trial was deemed to have a high risk of bias owing to both open-label administration of study drug and an outcome measure (insulin administration) that has the capacity to be influenced by the knowledge of treatment allocation [19]. With limited numbers of patients per study and short follow-up periods for the main outcome parameters, attrition bias was deemed low in all studies. Because most studies reported similar outcomes (Table 1), the risk of selective reporting between studies was considered low. The majority of studies had registered protocols demonstrating consistent reporting of outcomes, and in only one case was there a discrepancy between reported and registered outcomes [24]. Other potential sources of bias identified were an early termination due to slow enrolment [18], deviation from baseline reporting for some outcomes [22] and one study published as a letter to the editor with consequent brief reporting and unclear identification of sources of bias [31].

Efficacy of intervention
A measurement of glycaemic control was reported as the primary outcome in 17 of 19 included studies. We summarise all primary outcomes in Table 2.

Intra-operative glucose lowering
A number of studies assessed the effect of GLP-1 receptor stimulation as an adjunct to standard insulin therapy during cardiac surgery. The first of these randomised 20
| Author, year   | Participants, setting, n | DM, n (%) | Intervention duration | Intervention, dose, n | Comparator, n | Standard glycaemic therapy | Outcome parameters |
|---------------|--------------------------|-----------|-----------------------|-----------------------|---------------|-----------------------------|--------------------|
| Besch, 2017 [19] | CABG, OR + ICU n = 104 | 22 (21%)  | 48 h                 | Exenatide IV 25 ng/min | Standard glycaemic therapy n = 51 | Continuous insulin IV + bolus regimen | Glycaemia |
| Brackbill, 2012 [20] | CABG, ward, n = 62 | 62 (100%) | 4 d                  | Sitagliptin PO 100 mg q.d. n = 30 | Placebo n = 32 | Basal bolus insulin SC regimen | Glycaemia |
| Deane, 2009 [21] | Mechanically ventilated, ICU n = 7 | 0 (0%) | 240 min | GLP-1 IV 1.2 pmol/kg/min n = 11 | Placebo n = 7 | None | Glycaemia, Insulinaemia, Glucagon, GLP-1 |
| Deane, 2010 [22] | Mechanically ventilated, ICU n = 25 | 0 (0%) | 360 min | GLP-1 IV 1.2 pmol/kg/min n = 25 | Placebo n = 25 | None | Glycaemia, Gastric emptying, glucose absorption, Insulinaemia, Glucagon |
| Deane, 2011 [23] | Mechanically ventilated, ICU n = 11 | 11 (100%) | 240 min | GLP-1 IV 1.2 pmol/kg/min n = 11 | Placebo n = 11 | None | Glycaemia, Insulinaemia, C-peptide, glucagon, FFA |
| Galiatsatos, 2014 [24] | Surgical/burn, ICU n = 18 | 9 (50%) | 72 h | GIP IV 1.5 pmol/kg/min n = 9 | Saline n = 9 | Intensive insulin treatment protocol | Glycaemia, Insulin administration, glucagon, C-peptide, CV medication |
| Garg, 2017 [25] | In hospital, ward (74% surgical) n = 66 | 66 (100%) | 5 d | Saxagliptin PO 5 mg q.d. n = 33 | Basal bolus insulin SC regimen n = 33 | Corrective insulin bolus regimen | Glycaemia, Insulin administration, Treatment failure, LoS |
| Holmberg, 2014 [26] | CABG, OR n = 62 | 12 (19%) | 390 min | Exenatide IV 43 ng/min n = 21 | RIPC n = 20 / Placebo n = 21 | Unknown | Cardiac enzymes, Complications, LoS |
| Kar, 2015 [27] | Mechanically ventilated, ICU n = 20 | 0 (0%) | 300 min | GIP IV 4 pmol/kg/min n = 20 | Placebo n = 20 | None | Glycaemia, Gastric emptying, glucose absorption, insulinaemia |
| Kohl, 2014 [28] | CABG, OR n = 77 | 11 (14%) | 72 h | GLP-1 IV 1.5 pmol/kg/min n = 37 | Placebo n = 40 | Continuous insulin IV + bolus regimen | Glycaemia, Insulinaemia, glucagon, GLP-1, cortisol, FFA |
| Lee, 2013 [29] | Mechanically ventilated, ICU n = 20 | 0 (0%) | 300 min | GIP IV 4 pmol/kg/min n = 20 | Standard glycaemic therapy n = 20 | GLP-1 IV 1.2 pmol/kg/min (300 min) | Glycaemia, Insulinaemia, glucagon, GLP-1, GIP, |
| Lips, 2017 [17] | CABG, OR n = 38 | 26 (68%) | 72 h | Exenatide IV 20 ng/min n = 19 | Placebo n = 19 | Intensive insulin treatment protocol | Glycaemia, Echocardiography, CV medications, complications |
| Meier, 2004 [29] | Major surgery, ward n = 8 | 100 (100%) | 8 h | GLP-1 IV 1.2 pmol/kg/min n = 8 | Placebo n = 8 | None | Glycaemia, Insulinaemia, C-peptide, glucagon, GLP-1 |
| Miller, 2017 [30] | Mechanically ventilated, ICU n = 12 | 0 (0%) | 270 min | GLP-1 IV 1.2 pmol/kg/min | Placebo n = 12 | None | Glycaemia, Glucose absorption |
### Table 1: Study characteristics (Continued)

| Author, year | Participants, setting, n | DM, n (%) | Intervention duration, h | Intervention, dose, n | Comparator, n | Standard glycaemic therapy | Outcome parameters |
|--------------|---------------------------|-----------|--------------------------|-----------------------|--------------|---------------------------|--------------------|
| Müßig, 2008 [31] CABG, ICU n = 20 | 100 (100%) | 12 | GLP-1 IV 3.6 pmol/kg/min n = 10 | Continuous insulin IV n = 10 | Corrective insulin bolus regimen | Glycaemia | Insulin administration, haemodynamics |
| Pasquel, 2017 [32] In hospital, ward (16% surgical) n = 277 | 100 (100%) | 10 | Sitagliptin PO 100 mg q.d. n = 138 | Bolus insulin regimen n = 139 | Basal (glargine) insulin regimen | Glycaemia | Insulin administration, complications, treatment failure |
| Polderman, 2018 Surgical, OR n = 150 | 100 (100%) | 2 | Liraglutide SC 0.6 mg + 1.2 mg n = 44 | GIK infusion n = 53/Bolus insulin algorithm n = 53 | Bolus insulin treatment algorithm | Glycaemia | Insulin administration, Potassium, nausea, complications |
| Sokos, 2007 [34] CABG, OR n = 20 | 5 (25%) | 60 | GLP-1 IV 1.5 pmol/kg/min n = 10 | Standard insulin therapy n = 10 | Standard insulin therapy | Glycaemia | LVEF, haemodynamics |
| Umpierrez, 2014 In hospital, ward (45% surgical) n = 90 | 100 (100%) | 10 | Sitagliptin PO 100 mg q.d. n = 27 / Sitagliptin + basal insulin n = 29 | Basal bolus insulin regimen n = 26 | Correction bolus insulin regimen | Glycaemia | Insulin administration, complications, treatment failure |

**Abbreviations:** b.i.d. Twice per day, CABG Coronary artery bypass grafting, CV Cardiovascular, d Days, DM Diabetes mellitus, FFA Free fatty acids, GIK Glucose-insulin-potassium infusion, GIP Gastric inhibitory polypeptide, GLP-1 Glucagon-like peptide-1, h Hours, ICU Intensive care unit, IV Intravenously, LoS Length of stay, min Minutes, LVEF Left ventricular ejection fraction, OR Operating room, PO By mouth, q.d Once per day, RIPC Remote ischaemic preconditioning, SC Subcutaneous

All secondary outcomes are in italics
patients to a continuous intravenous infusion of GLP-1 (1.5 pmol kg$^{-1}$ min$^{-1}$) or placebo, commencing 12 h pre-operatively and continuing for 48 h post-operatively. GLP-1 resulted in lower mean glucose in the pre- and peri-operative periods, with nearly half the insulin administered to achieve comparable glycaemic control in the post-operative periods [34]. In 77 patients undergoing elective cardiac surgery, using the same dose of intravenous GLP-1 infused intra-operatively, Kohl and colleagues reported that mean blood glucose values were 0.68 mmol L$^{-1}$ lower for subjects receiving GLP-1 compared with those receiving placebo (95% CI, 0.13–1.22 mmol L$^{-1}$; $P = 0.015$) [27]. Lipš and colleagues randomised 38 patients with decreased left ventricular function undergoing coronary artery bypass grafting (CABG) to a 72-h infusion of intravenous exenatide (20 ng min$^{-1}$) or placebo as an adjuvant to standard insulin therapy [17]. Patients receiving exenatide demonstrated lower peri-operative mean blood glucose (6.4 ± 0.5 vs. 7.3 ± 0.8 mmol/L; $P < 0.001$) and a greater percentage of time in the target range (4.5–6.5 mmol/L (54.8% ± 14.5% vs. 38.6% ± 14.4%; $P = 0.001$). In a similar study of 104 patients undergoing elective CABG, Besch and colleagues did not observe a statistical difference in the glycaemic outcome of interest (time in target range) between intravenous exenatide (25 ng min$^{-1}$) and placebo; however, exenatide was insulin-sparing with a longer time to commencement of insulin and significantly less insulin administered during the first 6 h following surgery [31].

Studies assessing the efficacy of the oral DPP-IV inhibitor sitagliptin for post-operative glycaemic control in patients with T2DM have reported varied results. In the study by Brackbill and colleagues the post-CABG addition of sitagliptin (100 mg once daily) to standard subcutaneous basal insulin and regular oral hypoglycaemic agents did not result in any difference in glycaemia or insulin administration [20]. Two related studies on the ward, one [33] a pilot preceding a larger trial [32], which included both medical and surgical patients (Table 1), assessed sitagliptin (100 mg once daily) as an adjunct to a basal insulin regimen. The primary outcome of the larger trial was non-inferiority of mean blood glucose. Sitagliptin group was non-inferior to standard care and was associated with less total daily insulin requirement (24 ± 16 U/d vs. 34 ± 20 U/d; $P < 0.001$) [32]. Garg and colleagues compared the oral DPP-IV inhibitor saxagliptin (5 mg once daily) with basal bolus insulin in
a non-critically ill population of hospitalised patients with T2DM, predominantly in the post-operative period [35]. Saxagliptin was non-inferior to basal bolus insulin for glycaemic control as determined by the daily mean blood glucose (primary outcome), with saxagliptin treatment causing less glycaemic variability [35].

**Intensive care unit**
Deane and colleagues have assessed continuous intravenous infusions of GLP-1 in a series of cross-over trials in heterogeneous cohorts of mechanically ventilated patients [21–23, 30]. At a dose of 1.2 pmol kg\(^{-1}\) min\(^{-1}\) infused over 270 to 330 min, GLP-1 reduced the glycaemic response to small intestinal nutrient delivery in patients with T2DM [23] and to intra-gastric and small intestinal nutrient delivery in patients not known to have T2DM [21, 22, 30]. Enteral nutrient-stimulated hyperglycaemia was attenuated but not suppressed completely at this dose, with the glucose-lowering effect more prominent in those patients without a history of diabetes. This group also evaluated the glycaemic effect of intravenous infusions of GIP during intra-gastric and small intestinal nutrient administration in mechanically ventilated patients, and, in contrast to the profound glucose-lowering effect of GIP in health, they reported no glucose-lowering effect when GIP was given as stand-alone therapy or added to GLP-1 [26, 28]. Galiatsatos and colleagues compared an extended intravenous GLP-1 infusion (1.5 pmol kg\(^{-1}\) min\(^{-1}\) for 72 h) with placebo as an adjunct to intensive insulin therapy in critically ill surgical patients. They reported no difference in mean blood glucose or insulin use between groups, but substantially less glycaemic variability (given by the co-efficient of variation of mean glucose) was observed in the GLP-1 cohort [24].

**Hypoglycaemia**
Data regarding hypoglycaemia are summarised in Table 3. The threshold to diagnose moderate hypoglycaemia ranged from < 2.8 to < 4.0 mmol/L. The incidence of moderate hypoglycaemia in the incretin arm varied from zero to 17%, except for one outlier with a reported incidence of 36% (8 of 23 patients) [25]. In the latter trial intravenous exenatide was infused at double the dose of subsequent trials, and it is unclear whether insulin was concurrently administered [25]. Meta-analysis revealed no difference in incidence of hypoglycaemia (incretin-based therapy 36 of 484 [7.4%] vs. comparator 36 of 540 [6.7%], \(P = 0.96\)). Of note, incretin-based therapies were administered with insulin in 10 of the 14 studies reporting hypoglycaemia (Table 1).
Non-glycaemic effects
Owing to the heterogeneity of definitions and infrequency of reporting of non-glycaemic end-points, quantitative analysis of these data was not possible. Plasma insulin and glucagon concentrations were reported in eight studies [21–24, 26–28]. GLP-1 was reported to increase plasma insulin levels [23, 29] or insulin/glucose ratios [21, 22] in enterally fed critically ill and post-operative patients. However, this insulinotropic effect was not observed in studies that sampled blood intra-operatively in fasted patients [27, 34]. The effect of GLP-1 on glucagon concentration was similarly heterogeneous, with several studies reporting a glucagonostatic effect [24, 29, 34] and others reporting no difference [21, 22, 27]. The addition of GIP to a GLP-1 regimen in critically ill patients did not have an additional insulinotropic effect [28], and GIP as a sole agent was not shown to have an effect on plasma insulin or glucagon concentrations in critically ill patients [26].

In the critically ill, GLP-1 slows gastric emptying when emptying is relatively normal, but it appears to have minimal effect when emptying is already delayed [22], whereas GIP appears to have no effect on gastric motility [26]. Similarly, GLP-1 delayed enteral glucose absorption, even when nutrient was delivered directly into the small intestine [23, 30], whereas GIP had no effect [26].

Five studies compared the cardiovascular effects of GLP-1 or a GLP-1 receptor agonist with placebo [17, 24, 25, 31, 34]. In these studies there were no differences in cardiac enzymes [17, 25], echocardiographic measurements of left ventricular function [17, 34], haemodynamic parameters (heart rate, mean arterial pressure, pulmonary artery diastolic pressure) [31, 34] or vasoactive medication requirement [17, 24, 25, 31].

There was no difference in the incidence of post-operative nausea and vomiting in studies comparing placebo with intravenous exenatide [19], oral sitagliptin [32] and subcutaneous liraglutide [18]. However, pre-operative nausea was more common when subcutaneous liraglutide was administered the night before surgery (13% vs. 0%, \( P = 0.007, n = 150 \)) [18]. Incretin-based therapies have not been reported to increase post-operative complications or serious adverse events [17–19, 25, 32].

Diabetes mellitus
Eight studies were performed exclusively in patients with T2DM [18, 20, 23, 29, 31–33, 35], five studies in patients without T2DM [21, 22, 26, 28, 30] and a further six studies in mixed cohorts of patients with and without T2DM (Table 1) [17, 19, 24, 25, 27, 34]. None of the
### Table 3 Analysis of hypoglycaemia in reported studies

| Author, year | Threshold to define hypoglycaemia | Incretin n group | Comparator n group | Weight | Odds ratio M-H, random, 95% CI | P value | Odds ratio M-H, random, 95% CI |
|--------------|-----------------------------------|------------------|-------------------|--------|-----------------------------|---------|-----------------------------|
| Besch, 2017 [19] | 3.3 mmol L⁻¹ | 2 53 | 1 51 | 8.1% | 1.96 [0.17, 22.32] | 0.58 |
| Brackbill, 2012 [20] | 3.3 mmol L⁻¹ | 5 30 | 2 32 | 12.9% | 3.00 [0.54, 1681] | 0.06 |
| Deane, 2010 [22] | 3.0 mmol L⁻¹ | 0 25 | 0 25 | Not estimable | 1 |
| Galisatos, 2014 [24] | 2.8 mmol L⁻¹ | 1 9 | 3 9 | 78% | 0.25 [0.02, 304] | 0.58 |
| Garg, 2017 [35] | 3.9 mmol L⁻¹ | 1 33 | 1 33 | 5.7% | 1.00 [0.06, 1669] | 1 |
| Holmberg, 2014 [25] | 4.0 mmol L⁻¹ | 8 21 | 0 41 | 6.1% | 52.26 [2.83, 9666] | 0.003 |
| Kar, 2015 [26] | Not stated | 0 24 | 0 24 | Not estimable | 1 |
| Kohl, 2014 [27] | 3.8 mmol L⁻¹ | 0 37 | 0 40 | Not estimable | 1 |
| Lips, 2017 [17] | 3.3 mmol L⁻¹ | 2 19 | 4 19 | 11.9% | 0.44 [0.07, 276] | 0.12 |
| Meier, 2004 [29] | 4.0 mmol L⁻¹ | 0 8 | 0 8 | Not estimable | 1 |
| Müssig, 2008 [31] | Not stated | 0 10 | 0 10 | Not estimable | 1 |
| Pasquel, 2017 [33] | 3.9 mmol L⁻¹ | 13 138 | 17 139 | 24.7% | 0.75 [0.35, 1.60] | 0.45 |
| Polderman, 2018 [18] | 4.0 mmol L⁻¹ | 1 44 | 5 106 | 95% | 0.47 [0.05, 414] | 0.26 |
| Sokos, 2007 [34] | 3.3 mmol L⁻¹ | 1 10 | 2 10 | 7.4% | 0.44 [0.03, 588] | 0.39 |
| Umpierrez, 2014 [33] | 3.9 mmol L⁻¹ | 3 56 | 2 26 | 11.8% | 0.68 [0.11, 433] | 0.86 |
| Total (95% CI) | 484 540 | 100% | 0.97 [0.47, 202] | 0.94 |

**M-H** Mantel-Haenszel
Heterogeneity: Tau² = 0.39, Chi² = 12.94, df = 9 (P = 0.17); I² = 30%
Test for overall effect: Z = 0.08 (P = 0.94)
studies recruiting mixed populations reported subgroup analyses according to diabetic status. Owing to the heterogeneity of interventions and outcomes, it was not possible to draw meaningful conclusions on the effects of incretins in patients with T2DM compared with those without.

**Discussion**

We systematically reviewed all randomised controlled trials of incretin-based interventions performed in the operating room and/or ICU setting and identified 19 studies which included 1410 patients in aggregate. Most studies reported a reduction in blood glucose or glycaemic variability when incretin-based therapies were used as a sole agent and/or a decrease in insulin administration when used as adjuvant therapy. Incretin-based therapies did not significantly reduce the incidence of hypoglycaemia. Incretin-based therapies did appear to attenuate glycaemic variability, although the latter was infrequently reported.

A number of studies attempted to delineate mechanisms underlying glucose-lowering in this cohort. The recognised insulinotropic effect of GLP-1 was consistently demonstrated in enterally fed patients, whereas glucagonostasis was less reliably reported. In small, single-centre studies, exogenous GLP-1 slowed gastric emptying in the setting of normal gastric motility and delayed intestinal glucose absorption, both of which likely contribute to attenuating nutrient stimulated hyperglycaemia [22, 30].

Although compliance with GLP-1 receptor agonists is relatively good in ambulant patients with T2DM, the primary reason for discontinuation of therapy is gastrointestinal discomfort, particularly nausea and vomiting [36, 37]. Critically ill and post-operative patients are at increased risk of nausea and vomiting, and it is therefore somewhat surprising that only three of the studies reported this side effect. Notwithstanding the relatively small number of patients studied, it is reassuring that incretin therapy did not appear to further increase the risk of post-operative nausea and vomiting.

Large trials in ambulant patients with T2DM have reported beneficial cardiovascular effects with GLP-1 receptor agonists [38–40]. This signal is supported by preliminary animal and observational human data identifying potential cardioprotective properties of incretin-based therapies [41, 42]. This provides a persuasive rationale for the use of GLP-1 in the setting of cardiac surgery. In murine models, GLP-1 decreases ischaemia-induced myocardial damage [41], and in patients with heart failure, exogenous GLP-1 has been associated with improvements in left ventricular ejection fraction, myocardial oxygen uptake and 6-min walk distance [42]. However, the most recent trial in patients with diabetes and heart failure observed no difference in time to death or rehospitalisation for heart failure [43].

None of the studies included in this review reported any differences in acute indices of cardiac performance between incretin-based therapies and control.

**Strengths and limitations**

Strengths of this systematic review include the structured search, complete retrieval of the identified research and validated methods in accordance with the PRISMA statement. However, there are some limitations. We found marked clinical heterogeneity between the studies, including the dose and type of incretin therapy and duration of intervention, ranging from 4 h to 10 days. In addition, there were substantial differences in the glycaemic control strategies of the control arms, ranging from blinded placebo to open-label intravenous insulin. The broad scope of this review revealed a marked heterogeneity in the populations studied, which included patients undergoing elective cardiac surgery, ward surgical patients and mechanically ventilated critically ill patients. Furthermore, there were trials performed exclusively in patients with pre-existing diabetes, whereas in other trials patients with pre-existing diabetes were excluded, and still others included both groups of patients. Inferences should therefore be circumspect because it is increasingly recognised that hyperglycaemia does not represent the same insult to all patients and may be modified by patients’ pre-morbid glycaemic control [44]. It should be noted, however, that the majority of included patients were diagnosed with DM. Although all of the studies assessed ‘glycaemic control’, there was substantial variation in the outcomes reported, such that meta-analysis was possible only on the variable of hypoglycaemia. Finally, most studies were small, single-centre trials and thus underpowered to detect differences in clinical and patient-centred outcomes and safety end-points.

**Future directions**

Taken together, these data signal the potential for incretin-based therapies, particularly GLP-1-based regimens, as effective glucose-lowering agents with a relatively low incidence of hypoglycaemia. However, owing to the limitations of the original studies, it is not possible to draw definitive conclusions regarding the role of incretin therapies in the operating room and ICU. Future studies are required to determine (1) the population most likely to benefit; (2) optimal dosing regimens, including the role for combination therapy with insulin; and (3) clinical efficacy and safety outcomes.

**Conclusions**

Incretin-based therapies represent a promising, novel approach to glucose control in the peri-operative
period and during critical illness, with a low risk of hypoglycaemia. Further studies with larger sample sizes [45] are required to determine the optimal agent and dosing regimen and effects on patient-centred outcomes.

**Additional file**

**Additional file 1:** Methodology of systematic review on incretins in peri-operative and intensive care (PDF 88 kb)

**Abbreviations**

CABG: Coronary artery bypass grafting; CV: Cardiovascular; DM: Diabetes mellitus; DPP-IV: Dipeptidyl peptidase IV; FFA: Free fatty acids; GIK: Glucose-insulin-potassium infusion; GIP: Glucose-dependent insulinotropic peptide; GLP-1: Glucagon-like peptide 1; ICU: Intensive care unit; IV: Intravenously; LoS: Length of stay; LVEF: Left ventricular ejection fraction; PO: By mouth; RiPC: Remote ischaemic preconditioning; SC: Subcutaneous; T2DM: Type 2 diabetes mellitus.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on request.

**Authors’ contributions**

AHH, MPP and JH were responsible for the data collection, data input, study design, analysis and drafting of the manuscript. MWH, JHD, BP, AMD and JH were responsible for critical review, revisions and editorial assistance. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Authors read and approved the final manuscript.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on request.

**Authors’ contributions**

AHH, MPP and JH were responsible for the data collection, data input, study design, analysis and drafting of the manuscript. MWH, JHD, BP, AMD and JH were responsible for critical review, revisions and editorial assistance. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

AHH, BP and JH receive ongoing research support from Novo Nordisk.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Anaesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Postbus 22660, 1105 AZ Amsterdam, the Netherlands.

2Intensive Care Unit, Royal Melbourne Hospital, 300 Grattan Street, Parkville, VIC 3060, Australia.

3Department of Endocrinology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Postbus 22660, 1105 AZ Amsterdam, the Netherlands.

4American Diabetes Association. Diabetes care in the hospital. Diabetes Care. 2016;39(Suppl 1):S99–104.

5. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Taori G, et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc. 2010;85: 217–24.

6. Krinsley JS, Schultz MJ, Sprock PE, Harmsen RE, van Braam Houckgeest F, van der Sluijs JP, et al. Mild hypoglycemia is independently associated with increased mortality in the critically ill. Crit Care. 2011;15:R173.

7. Ali NA, O’Brien JM, Dungan K, Phillips G, Marsh CB, Lemeshow S, et al. Glucose variability and mortality in patients with sepsis. Crit Care Med. 2008;36:2316–21.

8. Plummer MP, Finnis ME, Horsfall M, Ly M, Kar P, Abdelhamid YA, et al. Prior exposure to hyperglycaemia attenuates the relationship between glycaemic variability during critical illness and mortality. Crit Care Resusc. 2016;18:189–97.

9. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med. 2010;38:838–42.

10. Polderman JAW, Hollmann MW, DeVries JH, Preckel B, Hermanides J. Perioperative hyperglycaemia and glucose variability in gynecologic laparotomies. J Diabetes Sci Technol. 2016;10:145–50.

11. Plummer MP, Chapman MJ, Horowitz M, Deane AM. Incretins and the intensivist: what are they and what does an intensivist need to know about them? Crit Care. 2014;18:205.

12. Deane AM, Jeppesen PB. Understanding incretins. Intensive Care Med. 2014; 40:1751–4.

13. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–42.

14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2502.

15. Ouazen M, Hammad H, Fedorowicz Z, Elmaagarzy A, Rayyan— a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.

16. Higgins JPT, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

17. Lipti M, Mraz M, Kloučková J, Kopecký P, Dobiáš M, Klíšová L, et al. The effect of continuous exenatide infusion on cardiac function and perioperative glucose control in cardiac surgery patients: a single-blind, randomized, controlled trial. Diabetes Obes Metab. 2017;19:1818–22.

18. Polderman JAW, Van Steen SCJ, Thiel B, Godfried MB, Houweling PL, Hoffmann MW, et al. Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose–insulin–potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial. Anaesthesia. 2018;73:332–9.

19. Besch G, Perrotti A, Mauny F, Puyraveau M, Barteis M, Filoteaux G, et al. Clinical effectiveness of intravenous exenatide infusion in perioperative glycemic control after coronary artery bypass graft surgery. Anesthesiology. 2017;127:775–87.

20. Brackbill ML, Rahman A, Sandy JS, Starn MD, Hamilton AF. Adjunctive sitagliptin therapy in postoperative cardiac surgery patients: a pilot study. Int J Endocrinol. 2012;2012:1–6.

21. Deane AM, Chapman MJ, Fraser RJJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care. 2009;13:R67.

22. Deane AM, Chapman MJ, Fraser RJJ, Summers MJ, Zaknic AV, Storey JP, et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med. 2010;38:1237–46.

23. Deane AM, Summers MJ, Zaknic A, Chapman MJ, Fraser RJJ, Di Bartolomeo AE, et al. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care. 2011;15:R55.

24. Galiatsatos P, Gibson BR, Rabeie A, Carlson O, Egan JM, Shannon RP, et al. The glucose regulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study. Crit Care Med. 2014;42:2658–45.
25. Holmberg FEO, Ottas KA, Andresen C, Perko MJ, Møller CH, Engstrøm T, et al. Conditioning techniques and ischemic reperfusion injury in relation to on-pump cardiac surgery. Scand Cardiovasc J. 2014;48:241–8.

26. Kar P, Cousins CE, Annink CE, Jones KL, Chapman MJ, Meier JJ, et al. Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study. Crit Care. 2015;19:20.

27. Kohl BA, Hammond MS, Cucchiara AJ, Ochoch EA. Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study. J Cardiothorac Vasc Anesth. 2014;28:618–25.

28. Lee MY, Fraser JD, Chapman MJ, Sundararajan K, Umapathysivam MM, Summer MJ, et al. The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycaemia in the critically ill. Diabetes Care. 2013;36:3333–6.

29. Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Ma N, et al. Intravenous glucagon-like peptide-1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med. 2004;32:848–51.

30. Miller A, Deane AM, Plummer MP, Cousins CE, Chapple LAS, Horowitz M, et al. Exogenous glucagon-like peptide-1 attenuates glucose absorption and reduces blood glucose concentration after small intestinal glucose delivery in critical illness. Crit Care Resusc. 2017;19:37–42.

31. Müssig K, Oncü A, Lindauer P, Heininger A, Aebert H, Unertl K, et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol. 2008;102:646–7.

32. Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5:125–33.

33. Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Woswick D, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. J Clin Endocrinol Metab. 2014;99:3430–5.

34. Sokos GG, Bolukoglu H, German J, Hentzos T, Magovern GJ, Maher TD, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824–9.

35. Garg R, Schuman B, Hurwitz S, Metzger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care. 2017;5:e000394.

36. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.

37. Sikirica M, Martin A, Wood R, Leth A, Percy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther. 2017;10:403–12.

38. Marso SP, Daniels GH, Brown-Grant K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.

39. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jønæs E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.

40. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.

41. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide-1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146–51.

42. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694–9.

43. Margules KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of lixisenatide on clinical stability among patients with advanced heart failure and reduced ejection fraction. JAMA. 2016;316:500–8.

44. Plummer MP, Bellomo R, Cousins CE, Annink CE, Sundararajan K, Reddi BAJ, et al. Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. Intensive Care Med. 2014;40:973–80.

45. Hulst AH, Visscher MJ, Godtfred MB, Thiel B, Gertitse BM, Scoby TV, et al. Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 for bridging of hyperglycaemia during cardiac surgery. BMJ Open. 2018;8:e022189.
Author/s:
Hulst, AH; Plummer, MP; Hollmann, MW; DeVries, JH; Preckel, B; Deane, AM; Hermanides, J

Title:
Systematic review of incretin therapy during peri-operative and intensive care

Date:
2018-11-14

Citation:
Hulst, A. H., Plummer, M. P., Hollmann, M. W., DeVries, J. H., Preckel, B., Deane, A. M. & Hermanides, J. (2018). Systematic review of incretin therapy during peri-operative and intensive care. CRITICAL CARE, 22 (1), https://doi.org/10.1186/s13054-018-2197-4.

Persistent Link:
http://hdl.handle.net/11343/253824

File Description:
Published version

License:
CC BY